Sign in
STSA Stock Price, Chart, Stats & News
Satsuma Pharmaceuticals, Inc.
Save
36.47M
Market cap
–
Current P/E
–
Forward P/E
STSA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 1.27% |
ROA | -125.89% |
ROE | 125.24% |
D/E | -0.00x |
Interest coverage ratio | -5457.46x |
STSA valuation
P/E | – |
P/S | – |
P/B | -0.17x |
P/CF | -0.68x |
P/FCF | -0.70x |
P/OCF | -0.68x |
PEG | -0.01x |
EV multiple | -0.90x |
About
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device.
Similar securities
Based on sector and market capitalization
Report issue